Company intelligence / Profile preview

ArriVent BioPharma

Newtown Square, Pennsylvania, United Statesarrivent.com ↗

Ownership: Public · AVBP
Employees: ~52
Development stage: Phase 1

Overview

ArriVent’s lead candidate firmonertinib has shown robust anti-tumor activity and CNS penetration in NSCLC patients with specific EGFR mutations. The global Phase III trial for first-line NSCLC with EGFR exon 20 insertions has completed enrollment. Interim data also show promising results for patients with PACC mutations. The company’s ADC pipeline is expanding through licensing deals and collaborations, including ARR-217/MRG007 targeting GI cancers now entering clinical development[5][7][9].

Therapeutic areas: Oncology
Modalities: Small molecules (tyrosine kinase inhibitors)Antibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

3 assets

ARR-002

2 more assets in the full pipeline.

Request access →

Partnerships

Shanghai Allist Pharmaceuticals Co., Ltd. – licensing of firmonertinib/furmonertinib[4]Lepu Biopharma Co., Ltd. – exclusive license for MRG007/ARR‑217 ADC program targeting GI cancers outside Greater China[1][7]Aarvik Therapeutics Inc. – research collaboration using modular antibody platform technology to develop novel oncology drugs[10]Beijing InnoCare Pharma Tech Co., Ltd.[4]Jiangsu Alphamab Biopharmaceuticals Co., Ltd.[4]

Financials

Market cap: $1.4B
Total revenue: $0
Enterprise value: $1B

Beyond the preview

Go deeper on ArriVent BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArriVent BioPharma.

Explore the full profile